Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus (ocrelizumab) for Multiple Sclerosis
Teva secures exclusive global rights to commercialize Polpharma Biologics' biosimilar candidate to Ocrevus (ocrelizumab), including both intrav
